CN102349920B - Sulfanilamide medicament composition for wound surface - Google Patents
Sulfanilamide medicament composition for wound surface Download PDFInfo
- Publication number
- CN102349920B CN102349920B CN2011102287229A CN201110228722A CN102349920B CN 102349920 B CN102349920 B CN 102349920B CN 2011102287229 A CN2011102287229 A CN 2011102287229A CN 201110228722 A CN201110228722 A CN 201110228722A CN 102349920 B CN102349920 B CN 102349920B
- Authority
- CN
- China
- Prior art keywords
- weight portions
- sulfadiazine
- calcium
- laurocapram
- zinc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a sulfanilamide medicament composition for a wound surface. The medicament composition contains sulfadiazine zinc, sulfadiazine silver and laurocapram, and can further contain preservative and medicinal calcium salt. The medicament composition is prepared into clinically acceptable formulations such as gel, mucilage, film coating agent and the like according to a conventional process by adding medicinal auxiliary materials. The medicament composition has strong antibacterial and bacteriostatic effects, obviously shortens the healing time of the wound surface, has good pain easing effect, is safe, effective and convenient to use; and the composition has stable anti-freezing property.
Description
Technical field
The invention belongs to field of medicinal compositions, particularly a kind of sulfonamides compositions, its preparation method and by its pharmaceutical preparation of making.
Background technology
Silver sulfadiazine (SD-Ag), English Sulfadiazine Silver by name, chemistry Sulfadiazine Silver by name; Molecular formula is C
10H
9AgN
4O
2S, molecular weight: 357.14, chemical structural formula is as follows:
Silver sulfadiazine is the crystalline powder of white or off-white color, and chance light or heat are perishable, all do not dissolve in water, ethanol, chloroform or ether.
Silver sulfadiazine has extremely strong inhibitory action to burn dominant bacteria bacillus pyocyaneus etc., and silver salt has astriction, can make that burn wound is dry, incrustation and immediate union.
Zinc sulfadiazine (SD-Zn), English name: Sulfadiazine Zinc, chemistry SD-Zn dihydrate by name.Molecular formula: C
20H
18N
8O
4S
2Zn2H
2O, molecular weight: 599.94, its structural formula is:
Zinc sulfadiazine is the crystalline powder of white or off-white color; Odorless, tasteless; Meet light or heat perishable, all do not dissolve in water, ethanol, chloroform or ether.
The sulfadiazine of zinc sulfadiazine partly has bacteriostasis property.Zinc in zinc sulfadiazine, due to the DNA structure that can destroy antibacterial, also has bacteriostasis.Zinc ion is the indispensable trace element of human body, the function of a lot of enzymes in the wide participation internal metabolism, and human body has 20% zinc to concentrate on skin, and burned patient is in various degree the zinc deficiency state that is in all.Zinc sulfadiazine when protecting from infection, can improve local zinc amount, promotes the epithelial tissue growth.Use zinc sulfadiazine can compensate the zinc loss, thereby the enhancing body opposing is infected and the ability of wound healing.Zinc sulfadiazine has the dual-use function of infection control and wound healing.
The external single preparations of ephedrine of silver sulfadiazine (SD-Ag) and zinc sulfadiazine (SD-Zn) is usually used in treating empyrosis wound surface clinically to be infected, and outside the decapacitation infection control, also can impel wound surface drying, incrustation and promote healing.Silver sulfadiazine and zinc sulfadiazine compound preparation be the report of existing clinical practice also.
The silver sulfadiazine that has been reported and sulfadiazine Zn composition and compound preparation thereof exist the deficiency of different aspect.Chinese patent application 01107197.4 (publication number CN1312078A) discloses a kind of manufacture method of compound sulfadiazine zinc spreader, and this liniment contains the composition of calcium salt and antiseptic, but antifreeze, stabilizing effect is not ideal enough.Chinese patent application 02160214.X (publication number CN1513458A) discloses a kind of Compound Sulfadiazine Silver zinc ointment machin its preparation method, but skin irritation is large.In the burn and scald therapeutic process, the subinfection again of wound surface bacillus pyocyaneus and healing time are very long is the emphasis problem of this type of disease, also remains further to be captured.
Summary of the invention
One of purpose of the present invention is to provide a kind of new sulfonamides compositions, and said composition can be used for preparation treatment burn and scald and other infective wound surface medicines.
Sulfonamides compositions of the present invention contains zinc sulfadiazine, silver sulfadiazine and laurocapram, and wherein the weight ratio of zinc sulfadiazine, silver sulfadiazine and laurocapram is 50～500: 20～250: 3～6; Preferred weight ratio is 200: 100: 4～5; Most preferably weight ratio is 200: 100: 4.5.
Zinc sulfadiazine in sulfonamides compositions of the present invention can be both that dihydrate can be also anhydride.The water white thick liquid of laurocapram, almost odorless, tasteless, and in the time of 25 ℃, proportion is 0.900-0.926; For nonpolar transdermal enhancer, it can make cutin softening, strengthens permeability, improves part or whole body blood drug level, improves the preparation bioavailability.Transdermal enhancing effect and the working concentration of laurocapram are non-linear relation, and according to the difference of medicine, consumption is during greater than optium concentration, and its transdermal enhancing effect descends on the contrary.research worker of the present invention is surprised to find, work as zinc sulfadiazine, the weight ratio of silver sulfadiazine and laurocapram is 50～500: 20～250: 3～6 o'clock, compositions has well antibacterial, the wound healing effect, be better than not containing the zinc sulfadiazine of laurocapram, the sulfadiazine silver composition, but when Laurel Azone too high levels, the outer used time, produce certain skin irritation, so zinc sulfadiazine in the present composition, the weight ratio of silver sulfadiazine and laurocapram is 50～500: 20～250: 3～6, preferred weight ratio is 200: 100: 4～5, most preferably weight ratio is 200: 100: 4.5.Work as external-used burn and scald treating, slow metabolism when zinc sulfadiazine contacts with wound fluid with silver sulfadiazine, some drugs can enter blood from local absorption, general absorbtivity is lower than 1/10 of dosage, sulfadiazine blood drug level Yue Keda 10～20mg/L, when wound surface extensive, when dosage is large, absorb and increase, blood drug level can be higher.Sulfonamidemia concentration should not surpass 200 μ g/ml, and as surpassing this concentration, adverse reaction rate increases, and toxicity strengthens, and common untoward reaction comprises the anaphylaxiss such as visible local irritation, erythra, dermatitis, drug fever, myalgia, serum sickness like response.Skin irritation during the laurocapram too high levels may be by making the generation that obviously raises of sulfonamidemia concentration.
Can also contain medicinal calcium salt and antiseptic in sulfonamides compositions of the present invention.
Described antiseptic can be one or more the combination in methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, butoben, soluble metyl hydroxybenzoate, ethylparaben sodium, soluble propylhydroxybenzoate, nipabutyl sodium, benzoic acid, sorbic acid, benzalkonium bromide.The preferred methyl hydroxybenzoate of antiseptic.
Described medicinal calcium salt can be one or more the combination in calcium gluconate, Calcium d-tartrate, calcium citrate, polyenoic acid calcium, calcium lactate, calcium chloride, calcium hydrogen phosphate.The preferred calcium gluconate of medicinal calcium salt.
Calcium is one of indispensable element of human body, and calcium salt is the maximum a kind of inorganic salt of people's in-vivo content, and 1% calcium great majority are ionic condition and are present in skin, soft tissue, extracellular fluid and blood.Calcium can be kept the contraction of muscle and the transmission of neural impulse; The energy stimulating platelet, impel blood clotting, cell adhesion on wound; Can also control inflammation with edema, keep acid-base balance, suitable supplementary calcium also can reduce the too low tic that causes of calcium content.And antiseptic has the effect of sterilization and anticorrosion.
While containing medicinal calcium salt and antiseptic, in drug regimen of the present invention, the weight portion of each composition is, zinc sulfadiazine 50～500 weight portions, silver sulfadiazine 20～250 weight portions, laurocapram 3～6 weight portions, antiseptic 1～20 weight portion, medicinal calcium salt 1～150 weight portion.
The preferred weight mix proportion scheme one of pharmaceutical composition of the present invention:
Zinc sulfadiazine (dihydrate) 400 weight portions, silver sulfadiazine 220 weight portions, laurocapram 3 weight portions, antiseptic 4 weight portions, medicinal calcium salt 45 weight portions.
The preferred weight mix proportion scheme two of pharmaceutical composition of the present invention:
Zinc sulfadiazine (dihydrate) 40 weight portions, silver sulfadiazine 20 weight portions, laurocapram 6 weight portions, antiseptic 14 weight portions, medicinal calcium salt 130 weight portions.
The preferred weight mix proportion scheme three of pharmaceutical composition of the present invention:
Zinc sulfadiazine (anhydride) 280 weight portions, silver sulfadiazine 130 weight portions, laurocapram 5 weight portions, antiseptic 17 weight portions, medicinal calcium salt 3 weight portions.
The most preferred weight proportion of the present composition is zinc sulfadiazine 200 weight portions, silver sulfadiazine 100 weight portions, laurocapram 4.5 weight portions, calcium gluconate 5 weight portions, methyl hydroxybenzoate 8 weight portions.
Sulfadiazine class pharmaceutical composition of the present invention can prepare by the following method, directly or adopt suitable solvent or medium that each composition of compositions is mixed according to its ratio.
The medicine of the wound surface such as the treatment burn and scald take pharmaceutical composition of the present invention as raw material is through extracorporeal bacteria inhibitor test, freezing-thawing test and clinical efficacy checking, have the bacillus pyocyaneus bacteriostasis by force, shorten the wound healing natural law, safe and non-stimulating, need not to change dressings, and the characteristic of analgesia, good freezing protection effect.Really arrived attenuation synergistic, wound healing, shorten the burn and scald treatment phase, is conducive to analgesic effect in the burn and scald therapeutic process.
Another object of the present invention, be to provide a kind of pharmaceutical preparation by sulfonamides compositions preparation of the present invention.Pharmaceutical composition of the present invention, requirement according to target formulation, by common process direct or indirect add conventional pharmaceutic adjuvant, make clinical acceptable dosage form, as gel, mucilage, varnish, liniment, lotion, irrigation, enema, patch, suppository.
The present invention further provides a kind of gel of being made by sulfonamides compositions of the present invention.The major auxiliary burden of making gel can be sodium alginate, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, gelatin, carbomer, chitosan, tragakanta etc.
In a specific embodiment of the present invention, sulfa drugs composition gels of the present invention agent is by zinc sulfadiazine (anhydride) 200 weight portions, silver sulfadiazine 100 weight portions, laurocapram 4.5 weight portions, Buddhist nun's platinum methyl ester 8 weight portions, calcium gluconate 5 weight portions, sodium alginate 480 weight portions, glycerol 950 weight portions, and distilled water is made in right amount.Distilled water 7500 weight portions are heated to boiling, under agitation slowly add sodium alginate, continue to boil molten on boiling water bath, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, continue to boil after 10 minutes and weigh, add water and supply 10000 weight portions, be chilled to room temperature, colloid mill breast mill three times, fill, packing, obtain gel.
The specific embodiment
Following experiment and embodiment further illustrate the present invention, but are not construed as limiting the invention.
Embodiment 1
The preparation of sample 1-6
Distilled water 750g is heated to boiling, under agitation slowly add the 50g sodium alginate, continue to boil molten on boiling water bath,, to even pasty state, under agitation add the components such as zinc sulfadiazine, silver sulfadiazine, laurocapram, stir evenly, continue to boil after 10 minutes and weigh, add water and supply 1000g, be chilled to room temperature, colloid mill breast mill three times, obtain sample.Zinc sulfadiazine in each sample, silver sulfadiazine, laurocapram consumption are as follows:
Sample 1: zinc sulfadiazine (dihydrate) 20g silver sulfadiazine 10g laurocapram 2g
Sample 2: zinc sulfadiazine (dihydrate) 20g silver sulfadiazine 10g laurocapram 0.45g
Sample 3: zinc sulfadiazine (anhydride) 20g silver sulfadiazine 10g laurocapram 0.2g
Sample 4: zinc sulfadiazine (dihydrate) 20g silver sulfadiazine 10g laurocapram 20g
Sample 5: zinc sulfadiazine (anhydride) 20g silver sulfadiazine 10g laurocapram 5g
Sample 6: zinc sulfadiazine (dihydrate) 20g silver sulfadiazine 10g laurocapram 1g
Local irritation study
Animal: rabbit, large ear white race, body weight 2-2.5kg, male and female are regardless of, and by Third Military Medical University's Experimental Animal Center, are provided, and totally 14, choose 1.5 * 1.5cm for every
2Not damaged depilation district 4-10 piece, take consubstantiality and allosome contrast.
Dosage: 1.0ml/ piece, every animals received amount 4ml-12ml/ times/day.Route of administration: local coating, the damage zone skin practice are identical.Administration area: 1.5 * 1.5cm
2/ piece, the 4-12 piece/only.The medicament contact time: 24 hours.Observation index: observed and recorded 1,24,48,72 hours local responses.Observing time: 24,48,72 hours, totally three times.
Test method:
14 of rabbit, slough the hair of abdominal part with the NaS paste, 24 hours by checking the depilation district, confirms that skin zero damage can use, and after rabbit is lain on the back and is fixed in operating-table, chooses not damaged depilation skin 4-12 piece, every area 1.5 * 1.5cm
2.Take consubstantiality and allosome contrast, each tested membrane 0.1ml is coated on tested skin, through 24 hours, with warm saline, gently wipe each tested membrane away, carefully observed and recorded 1,24, local skin reaction in 48,72 hours.According to the criterion of skin irritation intensity, rear dermoreaction evaluation is scored to film at every turn.
Get the best result of observing dermoreaction for twice, then the best result addition of the erythema of commenting note and edema, obatained score is called " directly stimulating number " and estimates by the skin irritation degree of reagent according to the size of index.All indexes be 0 be divided into non-stimulated; Index≤2 are slight the stimulation, and index stimulated for moderate between 3 one 5 minutes; Index 〉=5 are serious the stimulation.
To the stimulation of injured skin, with injection needle, skin is divided into # shape wound at the position of filming, cause damaged skin.Then tested membrane is coated in the skin part of damage, other is with above-mentioned.
Table 1: skin irritation intensity criterion
Table 2: be coated with the film test parts-layout
Above-mentioned tested membrane, in the alternately coating of test position, ventrimeson both sides, is done the consubstantiality contrast.
Experimental result table 3: rabbit skin irritation response situation
# is injured skin
Illustrate: 10 tuerculodermas are carried out 14 rabbit respectively for the examination film in (1) every kind, wherein have 8 in the consubstantiality controlled trial of 8 rabbit, have 2 in the allosome control experiment of 5 rabbit.(2) in the table, listed mark shows dermoreaction piece number/experiment skin chunk number.
By as seen from Table 3, sample 1, sample 2, sample 3, sample 6, to very big part intact skin and injured skin vacuum response all, only 1/10 rabbit skin is the minimal irritation reaction, and the appearance minimal irritation reaction times of the sample 4 that laurocapram content is high and sample 5 is obviously more than all the other four samples.
Embodiment 2
Sample 7: take zinc sulfadiazine (dihydrate) 20g, silver sulfadiazine 10g, laurocapram 0.5g, Buddhist nun's platinum methyl ester 0.95g, calcium gluconate 0.4g, sodium alginate 68g, glycerol 135g, distilled water is appropriate.Distilled water 750g is heated to boiling, under agitation slowly add sodium alginate, continue to boil molten on boiling water bath,, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, continue to boil after 10 minutes and weigh, add water and supply 1000g, be chilled to room temperature, colloid mill breast mill three times, obtain sample.
Sample 8: take zinc sulfadiazine (dihydrate) 20g, silver sulfadiazine 10g, Buddhist nun's platinum methyl ester 0.95g, calcium gluconate 0.4g, sodium alginate 68g, glycerol 135g, distilled water is appropriate.Distilled water 750g is heated to boiling, under agitation slowly add sodium alginate, continue to boil molten on boiling water bath,, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, continue to boil after 10 minutes and weigh, add water and supply 1000g, be chilled to room temperature, colloid mill breast mill three times, obtain sample.
Freezing-thawing test: sample thief 7,8, sampling detects.Carry out freeze thawing 3 times circulation, each circulation should be under-10～-20 ℃ of conditions 2d, then investigate 2d under 37 ℃ of conditions, after test again sampling detect, contain and measure average value measured three times.
Table 4: freezing-thawing test measurement result
Per sample 7 with the testing result of sample 8, in the situation that other prescription compositions are identical as can be known, add the preparation of laurocapram more stable aspect outward appearance, pH value, silver sulfadiazine and zinc sulfadiazine content.
Embodiment 3
Sample 9: take zinc sulfadiazine (anhydride) 8000g, silver sulfadiazine 4000g, laurocapram 412g, Buddhist nun's platinum ethyl ester 1732g, polyenoic acid calcium 865g, gelatin 8000g, glycerol 5600g, distilled water is appropriate.Appropriate distilled water is heated to boiling, under agitation slowly add gelatin, continue to boil molten on boiling water bath,, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, add water and supply weight, stir evenly, be chilled to room temperature, colloid mill breast mill twice, the final 100000g sample that obtains.
Sample 10: take zinc sulfadiazine (anhydride) 8000g, silver sulfadiazine 4000g, Buddhist nun's platinum ethyl ester 1732g, polyenoic acid calcium 865g, gelatin 8000g, glycerol 5600g, distilled water is appropriate.Appropriate distilled water is heated to boiling, under agitation slowly add gelatin, continue to boil molten on boiling water bath,, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, add water and supply weight, stir evenly, be chilled to room temperature, colloid mill breast mill twice, the final 100000g sample that obtains.
The clinical efficacy experiment: wound surface is with 0.1% bromo geramine, or after the sterilization of 0.05% hibitane, shallow II degree empyrosis wound surface should be cut its epidermis, and dark II degree burn and scald is thoroughly removed beancurd sheet as far as possible, and III degree empyrosis wound surface does not need special handling.Male patient's 89 examples, female patient 76 examples, the age is more than 15 years old below 60 years old, 26.7 years old mean age.The sample Direct Uniform is applied in wound surface, easy to use, only need getting final product on uniform coating on original medicine layer.
Table 5: clinical experiment is comparison sheet as a result
9 compare with the clinical efficacy result of sample 10 per sample, sample 9 namely adds the preparation of laurocapram, wound healing to ulcer, shallow II degree, dark II degree patient and III degree burned patient has facilitation, has shortened the treatment time limit, has alleviated patient's misery.
Embodiment 4
Sample 11: take zinc sulfadiazine (dihydrate) 40g, silver sulfadiazine 18g, laurocapram 6g, Buddhist nun's platinum methyl ester sodium 14g, Calcium d-tartrate 26g, soluble starch 68g, glycerol 28g, distilled water is appropriate.Distilled water 700g is heated to boiling, under agitation slowly adds soluble starch, continue to boil on boiling water bath molten, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, add water to supply 1000g, be chilled to room temperature, stir, obtain sample.
Sample 12: take zinc sulfadiazine (dihydrate) 40g, silver sulfadiazine 18g, Buddhist nun's platinum methyl ester sodium 14g, Calcium d-tartrate 26g, soluble starch 68g, glycerol 28g, distilled water is appropriate.Distilled water 700g is heated to boiling, under agitation slowly adds soluble starch, continue to boil on boiling water bath molten, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, add water to supply 1000g, be chilled to room temperature, stir, obtain sample.
In Vitro Bacteriostasis experiment: adopt agar dilution to measure minimal inhibitory concentration (MIC).Select bacterial strain and agar culture medium to derive from Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
Test method: sample 11 and sample 12 are diluted to agar culture medium respectively to contain principal agent zinc sulfadiazine and silver sulfadiazine weight summation be 0.5% concentration, dilute with the multiple proportions method again, make the series concentration of " culture medium-medicine ", then the impouring diameter is in the plate of 9cm, each plate 20ml, each drug level prepare three parts, parallelly cultivate base; Cultivated 24 hours for 37 ℃, the asepsis growth person can inoculate each 5 microlitres of five kinds of bacterium liquid, in the agar surface of same drug level.24 hours observed results of 37 ℃ of constant temperature culture.Minimal inhibitory concentration (MIC) take the lowest drug concentration of complete antibacterial growth as this sample, repeated experiments three times, observed result.
Table 6: minimum biocidal property (MIC) testing result
The sample 11 that adds laurocapram, surpassed sample 12 to the fungistatic effect of staphylococcus aureus, bacillus pyocyaneus and Hemolytic streptococcus, but identical with sample 12 for colibacillary minimal inhibitory concentration.
Embodiment 5
Take zinc sulfadiazine (dihydrate) 20g, silver sulfadiazine 10g, laurocapram 0.5g, Buddhist nun's platinum methyl ester 0.85g, calcium gluconate 0.36g, calcium chloride 52g, water-soluble chitosan 146g, distilled water is appropriate.Distilled water 750g is heated to boiling, under agitation slowly adds water-soluble chitosan, continue to boil molten on boiling water bath, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, add water and supply 1000g, be chilled to room temperature, twice, colloid mill breast mill; With the cleaning, drying of bolt mould, liquid paraffin does lubricant applying and model is inner,, with extremely slightly overflowing die orifice in the medicine impouring bolt mould after the breast mill, lets cool, and after solidifying fully, part is overflowed in excision, opens model, obtains the suppository sample.
Embodiment 6
Take zinc sulfadiazine (dihydrate) 40g, silver sulfadiazine 18g, laurocapram 5g, Buddhist nun's platinum methyl ester sodium 2g, calcium citrate 26g, povidone iodine 8g, glycerol 16g, distilled water is appropriate.Under agitation suitably slowly adding glycerol in distilled water, continuing to stir, adding all the other components such as zinc sulfadiazine, silver sulfadiazine, stirring evenly, adding water to supply 1000g, stirring, microporous filter membrane, the aseptic film of crossing, obtain the irrigation sample.
Embodiment 7
Zinc sulfadiazine (anhydride) 200g, silver sulfadiazine 100g, laurocapram 4.5g, Buddhist nun's platinum methyl ester 8g, calcium gluconate 5g, sodium alginate 480g, glycerol 950g, and distilled water is appropriate.Distilled water 7500g is heated to boiling, under agitation slowly adds sodium alginate, continue to boil molten on boiling water bath, to even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir evenly, continue to boil after 10 minutes and weigh, add water and supply 10000g, be chilled to room temperature, colloid mill breast mill three times, fill, packing, make gel.
Claims (9)
1. a sulfonamides compositions, contain zinc sulfadiazine 200 weight portions, silver sulfadiazine 100 weight portions, laurocapram 4～5 weight portions.
2. sulfonamides compositions according to claim 1, zinc sulfadiazine 200 weight portions wherein, silver sulfadiazine 100 weight portions, laurocapram 4.5 weight portions.
3. according to claim 1-2 arbitrary described pharmaceutical compositions, wherein also contain 1～150 medicinal calcium salt of weight portion and 1～20 weight portion antiseptic.
4. pharmaceutical composition according to claim 3, wherein said medicinal calcium salt is: the combination of one or more in calcium gluconate, Calcium d-tartrate, calcium citrate, polyenoic acid calcium, calcium lactate, calcium chloride, calcium hydrogen phosphate; Wherein said antiseptic is: the combination of one or more in methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, butoben, soluble metyl hydroxybenzoate, ethylparaben sodium, soluble propylhydroxybenzoate, nipabutyl sodium, benzoic acid, sorbic acid, benzalkonium bromide.
5. pharmaceutical composition according to claim 4, wherein said medicinal calcium salt is calcium gluconate; Wherein said antiseptic is methyl hydroxybenzoate.
6. pharmaceutical composition according to claim 5, zinc sulfadiazine 200 weight portions wherein, silver sulfadiazine 100 weight portions, laurocapram 4.5 weight portions, calcium gluconate 5 weight portions, methyl hydroxybenzoate 8 weight portions.
7. the arbitrary described pharmaceutical composition of the claim 1-6 clinical acceptable pharmaceutical preparation of making, be selected from gel, mucilage, varnish, liniment, lotion, enema, patch, suppository, spray.
8. the application of the arbitrary described pharmaceutical composition of claim 1-6 in preparing the wound healing medicine.
9. sulfa drugs composition gels agent, contain zinc sulfadiazine 200 weight portions, silver sulfadiazine 100 weight portions, laurocapram 4.5 weight portions, methyl hydroxybenzoate 8 weight portions, calcium gluconate 5 weight portions, sodium alginate 480 weight portions, glycerol 950 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102287229A CN102349920B (en) | 2011-08-10 | 2011-08-10 | Sulfanilamide medicament composition for wound surface |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102287229A CN102349920B (en) | 2011-08-10 | 2011-08-10 | Sulfanilamide medicament composition for wound surface |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102349920A CN102349920A (en) | 2012-02-15 |
| CN102349920B true CN102349920B (en) | 2013-11-13 |
Family
ID=45573636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102287229A Active CN102349920B (en) | 2011-08-10 | 2011-08-10 | Sulfanilamide medicament composition for wound surface |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102349920B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115186B1 (en) | 2023-01-07 | 2024-10-15 | Cyndie Holst Family Trust | Topical burn cream |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832750A (en) * | 2016-03-11 | 2016-08-10 | 张晓燕 | Sulfanilamide composite capsule for treating infectious diseases and preparation method thereof |
| GR1009789B (en) | 2019-03-18 | 2020-08-03 | Ελενη Δημητριου Πατσιανιδη | Ointment for burns |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102091345A (en) * | 2010-12-28 | 2011-06-15 | 中国人民解放军军事医学科学院野战输血研究所 | Sodium alga acid composition and application thereof |
-
2011
- 2011-08-10 CN CN2011102287229A patent/CN102349920B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102091345A (en) * | 2010-12-28 | 2011-06-15 | 中国人民解放军军事医学科学院野战输血研究所 | Sodium alga acid composition and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 曾伟强等.银锌霜的制备和临床应用.《齐鲁药事》.2005,第24卷(第7期),416-417. |
| 银锌霜的制备和临床应用;曾伟强等;《齐鲁药事》;20051231;第24卷(第7期);416-417 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115186B1 (en) | 2023-01-07 | 2024-10-15 | Cyndie Holst Family Trust | Topical burn cream |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102349920A (en) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6778219B2 (en) | Igai adhesive protein products that suppress skin inflammation and their applications | |
| CN102387793B (en) | Antiseptic compositions comprising silver ions and menthol and uses thereof | |
| CN105012993B (en) | A kind of cation Medical Living Creature Gum antiseptic dressing and preparation method thereof | |
| CN108135745A (en) | Composition is formed for effective novel fast deposition film for the treatment of of wounds | |
| CN106344956A (en) | Chitosan antibacterial gel with effect of promoting healing and method for preparing chitosan antibacterial gel | |
| CN103083713A (en) | Sterile polymerized covering dressing for wound surface | |
| EA014391B1 (en) | Pharmaceutical composition for treating burns and a method for the production thereof | |
| WO2023231049A1 (en) | Antibacterial dressing for promoting scarless healing of wounds and preparation method therefor | |
| CN103083472A (en) | Nano silver anti-inflammatory gel for treating gynecologic inflammation and preparation method thereof | |
| CN105169455B (en) | A kind of burn and scald external application first aid medical dressing and preparation method thereof | |
| CN104257684B (en) | Milk cow nipple medicated bath plastics and preparation method thereof | |
| CN107961399A (en) | A kind of water-based body lotion containing complex antimicrobials | |
| CN102349920B (en) | Sulfanilamide medicament composition for wound surface | |
| CN105854021B (en) | With analgesia, the external used medicine of antibacterial double effects, preparation and preparation method thereof | |
| CN108404111B (en) | A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient | |
| RU2636530C2 (en) | Pharmaceutical compositions for treatment of wounds and burns | |
| CN102600195A (en) | Composite transdermal linimentum for pets as well as preparation method and application of composite transdermal linimentum | |
| RU2336877C1 (en) | Local antimicrobial agent | |
| RU2326667C1 (en) | Medicinal agent for treatment of suppurative-inflammatory skin and soft tissue diseases of different aetiology | |
| CN101070341A (en) | Antibacterial peptide without mutagenic action | |
| KR20190098269A (en) | Preservative compositions comprising unityol and dimethylsulfoxide, uses of the compositions and methods of treating wounds using the same | |
| CN100488572C (en) | Sulfadiazine salt high-molecular hydrogel dressing and its preparation method | |
| CN103446399B (en) | A kind of external application Chinese medicine pack preparation of Acne treatment and manufacturing process thereof | |
| CN100496508C (en) | Policresulen gelling agent, method for preparation the same and the pharmaceutical use thereof | |
| RU2367456C2 (en) | Antibacterial and necrolytic local pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 610101 Beijing Road, Longquanyi economic and Technological Development Zone, Chengdu, Sichuan, 166 Patentee after: CHENGDU NO.1 PHARMACEUTICAL Co.,Ltd. Address before: 610101 Beijing Road, Longquanyi economic and Technological Development Zone, Chengdu, Sichuan, 166 Patentee before: CHENGDU NO 1 PHARMACEUTICAL INST Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180815 Address after: 610000 133, east two ring road, Tianpeng Town, Pengzhou, Chengdu, Sichuan, 133 Patentee after: CHENGDU FIRST PHARMACEUTICAL Co.,Ltd. Address before: 610101 Beijing Road, Longquanyi economic and Technological Development Zone, Chengdu, Sichuan, 166 Patentee before: CHENGDU NO.1 PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |